Role change
Kimball Carr
Chairman of the Board
IVPR ·
INSPIRE VETERINARY PARTNERS, INC.
appointed Kimball Carr, our current Chief Executive Officer, as Chairman of the Board
Ready 8-Ks
38
Latest filing
March 2, 2026, 6:59 PM ET
Top materiality
0.90
Event mix
other_material ×17 · regulatory ×8 · leadership ×5
Sentiment
4 pos · 14 neg · 20 neu
Executive change
recent →
Recent 8-K filings for IVPR
Highest-materiality recent filing
Inspire Veterinary Partners receives Nasdaq delisting notice; suspension set for Nov 24, 2025
- Received delisting notice from Nasdaq on Nov 13, 2025 for failing minimum bid price requirement.
- Not eligible for compliance period due to reverse stock splits exceeding 250:1 cumulative ratio over past two years.
-
Director Erinn Thomas-Mackey resigns from Inspire Veterinary board
Erinn Thomas-Mackey resigned from the Board effective February 26, 2026.
-
Inspire Veterinary Partners delisted from Nasdaq, now trades on OTCQB under IVPR
Nasdaq denied Company's request to continue listing; common stock suspended from Nasdaq on Jan 21, 2026.
-
Inspire cancels $25K debt by issuing 2.5M shares to Target Capital 1 LLC
Entered Cancellation and Exchange Agreement on Jan 14, 2026 with Target Capital 1 LLC.
-
Inspire Veterinary increases authorized Class A common shares from 100M to 700M
Authorized Class A common shares increased from 100,000,000 to 700,000,000, effective January 9, 2026.
-
Inspire Veterinary issues $975K convertible note at 23% OID, 10% interest; director resigns
Issued $975K principal secured convertible note to Manetto Hill Fund for $750K; 10% interest, matures Dec 31, 2026.
-
Inspire Veterinary cancels $150K debt in exchange for 3M common shares at $0.05 each
Cancelled $150,000 of outstanding principal under June 2025 promissory note with Target Capital 1 LLC.
-
Inspire Veterinary issues 9.45M shares to 622 Capital for business development consulting
9,450,000 shares of Class A common stock issued as compensation for business development consulting services.
-
Inspire Veterinary holds annual meeting; all director nominees elected, auditor ratified
Kimball Carr, Larry Alexander, Phillip Balatsos, Charles Stith Keiser, Anne Murphy, Erin Thomas-Mackey, Timothy Watters elected as directors.
-
Inspire Veterinary lowers Series B floor price to $0.05, redeems 2,027 shares for $2.7M
Floor price reduced from $0.1879 to $0.05 per share for Series B Preferred Stock.
-
Inspire Veterinary Partners gets Nasdaq hearing date for delisting appeal on Jan 13, 2026
Previously reported non-compliance with Nasdaq minimum bid price rule (bid <$1 for 30 consecutive days).
-
Inspire Veterinary Partners receives Nasdaq delisting notice; suspension set for Nov 24, 2025
Received delisting notice from Nasdaq on Nov 13, 2025 for failing minimum bid price requirement.
-
Inspire Veterinary issues $357k convertible notes at 30% OID to two investors
Issued two Senior Convertible Promissory Notes, each $178,571 principal, to Keystone Capital Partners and Seven Knots at 30% OID, netting $250k.
-
Inspire Veterinary dismisses auditor Kreit & Chiu; going concern, material weaknesses cited
Dismissed Kreit & Chiu CPA LLP as independent auditor on October 16, 2025; no disagreements occurred.
-
Inspire Veterinary Partners sells 1,253 Series B preferred shares for $1.0M gross proceeds
Amended July 28 SPA to add new institutional investors, including KCP Fund I, LLC.
-
Inspire Veterinary regains Nasdaq compliance with $2.5M equity rule
Received formal Nasdaq notification on Aug 26, 2025 confirming compliance with Listing Rule 5550(b)(1).
-
Inspire Veterinary believes it regained Nasdaq equity compliance via $5M preferred stock sale
Company received Nasdaq deficiency notice on Apr 10, 2025 for stockholders' equity of $1.56M, below minimum requirement.
-
Inspire Veterinary Partners raises up to $10M via Series B convertible preferred stock
First closing generated ~$5M in cash and transferred securities; up to $4M additional at investor option.
-
Inspire Veterinary Partners acquires Debary Animal Clinic for ~$2.06M; adds ~$1.8M annual revenue
Total consideration: $925k for clinic assets ($832.5k cash + 54,734 restricted shares) and $1.132M cash for real estate.
-
Inspire Veterinary Partners issues $296,700 of convertible notes at 75% market conversion
$204,700 note issued to 1800 Diagonal Lending LLC with $24,564 interest, matures March 30, 2026.
-
Inspire Veterinary appoints CEO Kimball Carr as Chairman of the Board
Kimball Carr, current CEO, appointed Chairman effective May 1, 2025.
-
Inspire promotes Lynley Kees to CPO; YTD DVM hiring up 500%; acquires Debary Animal Clinic for $925K
Lynley Kees promoted from VP of HR to Chief People Officer, effective April 28, 2025; base salary $235K.
-
Inspire Veterinary enters CEO agreement with Kimball Carr; base $300k, bonus up to 62.5%
Base salary of $300,000 per annum; performance bonus of 45% (min) to 62.5% (max) of salary based on KPIs.
-
Inspire Veterinary Partners receives Nasdaq delisting notice for minimum equity deficiency
Nasdaq notified Inspire of non-compliance with minimum stockholders' equity requirement; equity reported as $1,562,005.
-
Inspire Veterinary raises $2.0M in registered direct offering; warrants could add $4.0M
Gross proceeds of $2.0M from sale of 1,092,896 shares (or pre-funded warrants) at $1.83/unit.
-
Inspire Veterinary enters empl. agreement with CFO Frank; $255K base, bonus up to 50%
Base salary of $255,000/year; bonus 36%-50% based on revenue, EBITDA, G&A, and M&A KPIs.
-
Inspire Veterinary increases authorized shares to 100M; regains Nasdaq bid price compliance
Amendment increases authorized Class A common shares to 100M, effective Feb 11, 2025, approved by majority stockholders on Jan 29, 2025.
-
Reverse stock split effective Jan 27, 2025 at 1:25 ratio; shares will trade on split-adjusted basis under symbol IVP.
-
Inspire Veterinary extends CFO Richard Frank's contract to March 1, 2025
CFO Richard Frank's employment agreement extended through March 1, 2025; terms unchanged.
-
Inspire Veterinary Partners approves 1-for-25 reverse stock split to regain Nasdaq compliance
Reverse split effective Jan 3, 2025, converting every 25 shares into 1 share.
-
Inspire Veterinary Partners enters $25M ATM stock offering with H.C. Wainwright
Up to $25M in common stock may be sold at market through H.C. Wainwright as sales agent.
-
Inspire Veterinary faces Nasdaq bid price non-compliance; gets public reprimand for prior offering
Demonstrated compliance with Nasdaq minimum equity rule; subject to Mandatory Panel Monitor until Dec 12, 2025.
-
Offering of 10,000,000 shares of Class A common stock at $0.25 per share.
-
Inspire Veterinary Partners cuts warrant exercise price to $0.20 for 2.5M shares
Reduced exercise price of 2,500,000 warrants from $1.00 to $0.20 effective Oct 8, 2024.
-
Nasdaq Staff Determines Inspire Veterinary Failed Rule 5635(d); Faces Delisting
Staff letter dated Sep 24, 2024, says July 15 'best efforts' offering didn't qualify as public offering.
-
Inspire Veterinary sells Kauai clinic to related party for $2.16M; no proceeds
Sold Kauai Veterinary Clinic in Lihue, HI to Kauai RE Holdings for $2,162,781.
-
CEO Kimball Carr's employment agreement extended through February 1, 2025, effective July 8, 2024.
-
Inspire Veterinary closes $6M public offering of units with warrants
Gross proceeds of ~$6M from sale of 6M units at $1.00/unit; each unit includes a share or pre-funded warrant plus a warrant.
-
Nasdaq grants Inspire Veterinary Partners continued listing until Sept 4, 2024 with conditions
Company must file registration statement by June 15, 2024 for a public offering led by Spartan Capital Securities.
Executive changes
Materiality & sentiment trend
Max materiality 0.90 · Median 0.60 · Most common event other_material